US2008081780A1PendingUtilityA1

Identification of oligoadenylate synthetase-like genes

48
Assignee: BAYLOR COLLEGE MEDICINEPriority: May 17, 2002Filed: Jun 17, 2007Published: Apr 3, 2008
Est. expiryMay 17, 2022(expired)· nominal 20-yr term from priority
Inventors:Martin MatzukYuchen BaiWei Yan
A61P 35/00A61P 35/02A61P 9/00A61P 43/00A61P 35/04A61P 9/08A61P 9/10A61P 15/08C12N 9/1241A61P 15/16A61P 21/00A61P 1/04A61P 13/08A61P 13/10A61P 17/06A61P 15/18A61K 38/00A61P 19/02A01K 2217/05A61P 1/02
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

Claims

exact text as granted — not AI-modified
1 - 122 . (canceled)  
     
     
         123 . An isolated polynucleotide sequence encoding a protein, wherein said polynucleotide is selected from the group consisting of: 
 (a) a polynucleotide sequence encoding SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12;    (b) a polynucleotide sequence encoding an amino acid sequence having at least 60% identity with SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12;    (c) an isolated nucleic acid molecule that hybridizes with the polynucleotide sequence of (a) under hybridization conditions of 0.02 M to about 0.15 M NaCl at temperatures of about 50° C. to about 70° C.; and    (d) an isolated polynucleotide sequence that is complementary to (a), (b) or (c).    
     
     
         124 . The polynucleotide of  claim 123 , wherein said polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11.  
     
     
         125 . An isolated polypeptide sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.  
     
     
         126 . The polynucleotide of  claim 123 , wherein the polynucleotide is an antagonist of SEQ ID NO:23, SEQ ID NO:25 or SEQ ID NO:27.  
     
     
         127 . The polynucleotide of  claim 126 , wherein the polynucleotide is antagonist of SEQ ID NO:24, SEQ ID NO:26 or SEQ ID NO:28.  
     
     
         128 . A pharmaceutical composition comprising a modulator of OASL expression or activity dispersed in a pharmaceutically acceptable carrier.  
     
     
         129 . The composition of  claim 128 , wherein the modulator suppresses transcription of an Oasl gene, wherein the Oasl gene is selected from the group consisting of Oasl6, Oasl7, Oasl8, Oasl9, Oasl10 and Oasl11.  
     
     
         130 . The composition of  claim 128 , wherein the modulator enhances transcription of an Oasl gene, wherein the Oasl gene is selected from the group consisting of Oasl6, Oasl7, Oasl8, Oasl9, Oasl10 and Oasl11.  
     
     
         131 . The composition of  claim 128 , wherein the modulator inhibits the activity of OASL, wherein OASL is selected from the group consisting of OASL6, OASL7, OASL8, OASL9, OASL10 and OASL11.  
     
     
         132 . The composition of  claim 128 , wherein the modulator stimulates the activity of OASL, wherein OASL is selected from the group consisting of OASL6, OASL7, OASL8, OASL9, OASL10 and OASL11.  
     
     
         133 . The composition of  claim 128 , wherein the modulator is selected from the group consisting of a polypeptide, a small molecule, a polynucleotide sequence and an expression vector.  
     
     
         134 . A method of modulating mRNA degradation in a germ cell or early embryo of an animal comprising the step of administering to the animal an inhibitor of OASL activity.  
     
     
         135 . The method of  claim 134 , wherein said germ cell is an oocyte or egg.  
     
     
         136 . The method of  claim 134 , wherein said germ cell is spermatid or spermatazoon.  
     
     
         137 . The method of  claim 134 , wherein the inhibitor suppresses transcription of an Oasl gene, wherein the Oasl gene is selected from the group consisting of Oasl6, Oasl7, Oasl8, Oasl9, Oasl10 and Oasl11.  
     
     
         138 . The method of  claim 134 , wherein the inhibitor is selected from the group consisting of a polypeptide, a polynucleotide sequence and an expression vector.  
     
     
         139 . A method of contraception comprising administering to an animal an effective amount of a modulator of OASL activity dispersed in a pharmacologically acceptable carrier, wherein said amount is capable of decreasing conception.  
     
     
         140 . The method of  claim 139 , wherein the OASL is selected from the group consisting of OASL6, OASL7, OASL8, OASL9, OASL10, and OASL11.  
     
     
         141 . The method of  claim 140 , wherein the OASL is OASL6.  
     
     
         142 . A method of modulating mRNA degradation in a germ cell or early embryo of an animal comprising the step of administering to the animal a stimulator of OASL activity.  
     
     
         143 . The method of  claim 142 , wherein said germ cell is an oocyte or egg.  
     
     
         144 . The method of  claim 142 , wherein said germ cell is spermatid or spermatazoon.  
     
     
         145 . The method of  claim 142 , wherein the stimulator enhances transcription of an Oasl gene, wherein the Oasl gene is selected from the group consisting of Oasl6, Oasl7, Oasl8, Oasl9, Oasl10 and Oas11.  
     
     
         146 . The method of  claim 142 , wherein the stimulator is selected from the group consisting of a polypeptide, a polynucleotide sequence and an expression vector.  
     
     
         147 . A method of enhancing fertility comprising administering to an animal an effective amount of a modulator of OASL activity dispersed in a pharmacologically acceptable carrier, wherein said amount is capable of decreasing conception.  
     
     
         148 . The method of  claim 147 , wherein the OASL is selected from the group consisting of OASL6, OASL7, OASL8, OASL9, OASL10, and OASL11.  
     
     
         149 . The method of  claim 148 , wherein the OASL is OASL6.  
     
     
         150 . A method of diagnosing infertility comprising identifying a mutation in an OASL polypeptide or polynucleotide.  
     
     
         151 . A method of modulating a hyperproliferative disease comprising administering to an animal an effective amount of a modulator of OASL activity dispersed in a pharmacologically acceptable carrier.  
     
     
         152 . The method of  claim 151 , wherein the OASL is selected from the group consisting of OASL6, OASL7, OASL8, OASL9, OASL10, and OASL11.  
     
     
         153 . The method of  claim 151 , wherein the hyperproliferative disease is further defined as cancer.

Join the waitlist — get patent alerts

Track US2008081780A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.